论文部分内容阅读
动脉粥样硬化性疾病严重危害人类健康。血脂代谢异常是引起动脉粥样硬化性疾病的主要原因。应用他汀降低低密度脂蛋白胆固醇(LDL-C)水平是心血管病患者血脂紊乱管理的基础。近来研究发现,应用他汀治疗且LDL-C水平达到治疗的靶点的患者血管残余风险仍然很高。甘油三酯(TG)升高和高密度脂蛋白胆固醇(HDL-C)降低是残余风险的重要危险因素,且HDL-C水平是独立于LDL-C水平的心血管危险预测因子,是进一步降低心血管危险因素的合理治疗目标,低HDL-C在血脂紊乱的心血管病患者中很常见,降低LDL到治目标同时升高HDL-C的治疗策略,可能获得更多的临床效益。
Atherosclerotic diseases are a serious risk to human health. Abnormal lipid metabolism is the main cause of atherosclerotic disease. The use of statins to reduce low-density lipoprotein cholesterol (LDL-C) levels in patients with cardiovascular disease is the basis for the management of dyslipidemia. Recent studies have found that patients treated with statins and LDL-C levels to achieve the target of treatment of patients with residual vascular risk is still high. Elevated triglyceride (TG) and decreased HDL-C are important risk factors for residual risk, and HDL-C is a predictor of cardiovascular risk independent of LDL-C and is further reduced The goal of a reasonable treatment of cardiovascular risk factors, low HDL-C in dyslipidemic cardiovascular disease is common, reduce LDL to treatment goals while raising HDL-C treatment strategies, may obtain more clinical benefits.